Magnetic Field Rotating / GSH Cancer Research Results

MFrot, Magnetic Field Rotating: Click to Expand ⟱
Features:
Rotary Magnetic field can be generated by a spinning magnet or magnets. Or it can be implemented with 2 or more coils, power with a phase shift between them (90 deg for 2 coil implementation) (60deg for 3 coil implementation)
Targets affected are mostly the same as for Magnet fields
Main differences
- may enhance the EPR effect allowing targeting of drugs to cancer cells
- acts as wireless stirrer, especially on magnetic particles(inducing eddy currents in water media)
- research for use in nano surgery, and mechanical destruction of cancer cells
- continue to highlight ability to raise ROS in cancer cell and lower ROS in normal cells
- RMF may be responsible for Ca2+ distribution to pass across the plasma membrane(differental affected for cancer and normal cells)

Pathways:
- induce ROS production in cancer cells, while decreasing ROS in normal cells. Ca2+ is critical and the Ca2+ balance is increased in cancer cells while decreased in normal cells (example for wound healing)
- ROS↑ related: MMP↓(ΔΨm), Ca+2↑, Cyt‑c↑, Caspases↑, DNA damage↑, cl-PARP↑, HSP↓, Prx,
- Raises AntiOxidant defense in Normal Cells: ROS↓, NRF2↑, SOD↑, GSH↑">GSH, Catalase↑,
- lowers Inflammation : NF-kB↓, COX2↓, p38↓, Pro-Inflammatory Cytokines : TNF-α↓, IL-6↓,
- inhibit Growth/Metastases : TumMeta↓, TumCG↓, MMPs↓, MMP2↓, MMP9↓, IGF-1↓, RhoA↓, NF-κB↓, TGF-β↓, ERK↓
- cause Cell cycle arrest : TumCCA↑,
- inhibits Migration/Invasion : TumCMig↓, TumCI↓, TNF-α↓, ERK↓,
- Others: PI3K↓, AKT↓, Wnt↓, AMPK, ERK↓, JNK,
- Synergies: < Others(review target notes), Neuroprotective, Cognitive,

- Selectivity: Cancer Cells vs Normal Cells

Rotating Magnetic Fields
Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 ROS (tumor-selective oxidative stress) ↑ ROS (P→R); sustained to cytotoxicity (G) ↔ minimal change or transient ↑ without injury (P→R) P, R, G Primary stress amplifier Oncomagnetic reports emphasize selective tumor ROS increase with normal-cell sparing in comparable exposure conditions
2 Mitochondrial ETC inhibition (Complex I/NADH:ubiquinone) ↓ Complex I / respiration (P→R) ↔ limited effect (P→R) P, R Bioenergetic collapse trigger Rotating/spinning fields are proposed to disrupt mitochondrial electron flow, driving ROS elevation upstream of ΔΨm loss
3 Ca²⁺ signaling (ER–mitochondria Ca²⁺ transfer / mitochondrial Ca²⁺ load) ↑ Ca²⁺ dysregulation (P→R) contributing to mitochondrial failure (G) ↔ buffered Ca²⁺ homeostasis (P→R) P, R, G Amplifies ETC/ROS-driven toxicity RMF-driven mitochondrial stress can propagate via Ca²⁺ transfer to accelerate ΔΨm loss and pro-death ER stress in tumor cells while sparing normal cells
4 Mitochondrial permeability transition pore (MPTP) ↑ sustained MPTP opening (R→G) ↔ resistant to opening P, R, G Mitochondrial point-of-no-return RMF-enhanced ROS and Ca²⁺ loading promote persistent MPTP opening in tumor mitochondria, driving energetic collapse and apoptosis while normal cells remain below the opening threshold
5 ΔΨm / mitochondrial membrane integrity ↓ ΔΨm (R); progresses (G) ↔ preserved R, G Mitochondrial failure threshold Matches the “energy factory” targeting concept described in Oncomagnetic mechanism narratives
6 GSH depletion GSH (R→G) ↔ maintained R, G Loss of redox buffering Cancer-selective inability to restore GSH is a key discriminator vs normal cells
7 NRF2 response (selectivity gate) ↔ delayed/insufficient NRF2 (R→G) ↑ NRF2 (R→G) R, G Adaptive protection Normal-cell sparing is consistent with competent NRF2-driven antioxidant defense
8 ER stress / UPR (CHOP commitment) ↑ ER stress (R); CHOP/apoptotic UPR (G) ↑ adaptive UPR (R); resolves (G) R, G Proteostasis failure ETC/ROS stress propagates to ER; commitment vs resolution diverges by cell robustness
9 DNA damage (oxidative; checkpoint markers) ↑ DNA damage (R→G) ↔ or repaired (G) R, G Checkpoint stress Interpreted as ROS-mediated consequence; reported as increased damage markers in some translational datasets
10 LDH / glycolytic vulnerability ↓ LDH performance / ↓ glycolytic flux (R→G) ↔ metabolic flexibility R, G Metabolic choke Cancer glycolysis becomes unstable when NADH/NAD+ and redox buffering are stressed
11 TrxR / thioredoxin system overload ↓ reserve (R→G) ↔ preserved R, G Parallel antioxidant collapse Useful when GSH data are mixed; TrxR can be the limiting system under sustained ROS
Time-Scale Flag: TSF = P / R / G
  P: 0–30 min (physical / electron / radical effects)
  R: 30 min–3 hr (redox signaling & stress response)
  G: >3 hr (gene-regulatory adaptation)
MPTP: opening represents a mitochondrial commitment event integrating ROS and Ca²⁺ stress; sustained opening indicates irreversible bioenergetic failure.


GSH, Glutathione: Click to Expand ⟱
Source:
Type:
Glutathione (GSH) is a thiol antioxidant that scavenges reactive oxygen species (ROS), resulting in the formation of oxidized glutathione (GSSG). Decreased amounts of GSH and a decreased GSH/GSSG ratio in tissues are biomarkers of oxidative stress.
Glutathione is a powerful antioxidant found in every cell of the body, composed of three amino acids: cysteine, glutamine, and glycine. It plays a crucial role in protecting cells from oxidative stress, detoxifying harmful substances, and supporting the immune system.
cancer cells can have elevated levels of glutathione, which may help them survive in the oxidative environment created by the immune response and chemotherapy. This can make cancer cells more resistant to treatment.
While glutathione can be obtained from certain foods (like fruits, vegetables, and meats), its absorption from supplements is debated. Some people take N-acetylcysteine (NAC) or other precursors to boost glutathione levels, but the effects on cancer prevention or treatment are still being studied.
Depleting glutathione (GSH) to raise reactive oxygen species (ROS) is a strategy that has been explored in cancer research and therapy.
Many cancer cells have altered redox states and may rely on GSH to survive. Increasing ROS levels can induce stress in these cells, potentially leading to cell death.
Certain drugs and compounds can deplete GSH levels. For example, agents like buthionine sulfoximine (BSO) inhibit the synthesis of GSH, leading to its depletion.
Cancer cells tend to exhibit higher levels of intracellular GSH, possibly as an adaptive response to a higher metabolism and thus higher steady-state levels of reactive oxygen species (ROS).

"...intracellular glutathione (GSH) exhibits an astounding antioxidant activity in scavenging reactive oxygen species (ROS)..."
"Cancer cells have a high level of GSH compared to normal cells."
"...cancer cells are affluent with high antioxidant levels, especially with GSH, whose appearance at an elevated concentration of ∼10 mM (10 times less in normal cells) detoxifies the cancer cells." "Therefore, GSH depletion can be assumed to be the key strategy to amplify the oxidative stress in cancer cells, enhancing the destruction of cancer cells by fruitful cancer therapy."

The loss of GSH is broadly known to be directly related to the apoptosis progression.


Scientific Papers found: Click to Expand⟱
186- MFrot,  MF,    Selective induction of rapid cytotoxic effect in glioblastoma cells by oscillating magnetic fields
- in-vitro, GBM, GBM - in-vitro, Lung, NA
mt-ROS↑, Casp3↑, selectivity↑, TumCD↑, ETC↓, H2O2↑, eff↓, GSH↑, MMP↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress

GSH↑, 1,   H2O2↑, 1,   mt-ROS↑, 1,  

Mitochondria & Bioenergetics

ETC↓, 1,   MMP↓, 1,  

Cell Death

Casp3↑, 1,   TumCD↑, 1,  

Drug Metabolism & Resistance

eff↓, 1,   selectivity↑, 1,  
Total Targets: 9

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: GSH, Glutathione
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:192  Target#:137  State#:%  Dir#:2
wNotes=0 sortOrder:rid,rpid

 

Home Page